amr industry alliance

uniting to act on antimicrobial resistance

The AMR Industry Alliance is one of the largest private sector coalitions set up to provide sustainable solutions to curb antimicrobial resistance, with over 100 biotech, diagnostics, generics and research-based pharmaceutical companies and associations joining forces.

read more

We drive and measure the life-sciences industry progress to curb antimicrobial resistance in four different areas:

Invest in R&D to meet public health needs with new innovative diagnostics & treatments
Improve access to high-quality antibiotics and ensuring that new ones are available to all
Work to reduce the development of antimicrobial resistance
Support measures to reduce environmental impact from production of antibiotics

shared goals

We are uniting efforts to reduce the development of antimicrobial resistance, invest in R&D to meet public health needs and improve access to antibiotics, vaccines and diagnostics.

progress report

In 2018, the Alliance published its first progress report that provides unique insights into the practical steps its members are taking to respond to AMR. The findings of the report illustrate both the challenges the healthcare sector faces in tackling AMR and how the industry is essential to winning this battle.

in action

Our case studies provide snap-shots from across the life-sciences industry, share information on the tangible steps we are taking to invest in new research to develop new antibiotics and vaccines, prevent infection ,and improve appropriate use of antibiotics.

latest news

18/09/2019

AMR Industry Alliance Round-Up, Issue No.2, September 2019

Welcome to the second issue of the Alliance Round-Up – written for more than 100 biotech, diagnostic, generic and R&D pharma companies that are members of the AMR Industry Alliance, as well as...

Read more
29/07/2019

New brochure to discover the AMR Industry Alliance in 2 minutes

Representing more than 100 biotechnology, diagnostics, generics and research-based pharmaceutical companies and associations, the AMR Industry Alliance is one of the largest private sector coalitions...

Read more
13/06/2019

AMR Industry Alliance Round-Up, Issue No.1, June 2019

  This is the first issue of "Alliance Round-Up" written for the more than 100 biotech, diagnostic, generic and pharma companies who are members of the AMR Industry Alliance, as well as people...

Read more

amr in numbers

AMR Impact

Life-sciences at the forefront of the battle against AMR

Development of National Action Plans

R&D

Biotechs

Diagnostics

from the blog

Posted on 13/09/2019
By Manos Perros, President and CEO, Entasis Therapeutics

The new reality for next-gen antibiotics

The future of antibiotic development lies in targeted approaches that can deliver novel drugs tailored to tackle those highly resistant pathogens with greatest medical need. The world of antibacterial therapy as we know it is changing fast. For decades we have used antibiotics empirically, treat...

Read more view all

stay informed

Subscribe to receive our updates

  • I consent to the storage of my data according to the Privacy Policy